Masson Serge, Latini Roberto
Department of Cardiovascular Research, Laboratory of Cardiovascular Clinical Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
Am J Cardiol. 2008 Feb 4;101(3A):56-60. doi: 10.1016/j.amjcard.2007.11.024.
In patients with chronic heart failure (HF), amino-terminal pro-B-type natriuretic peptide (NT-proBNP) levels are among the strongest independent predictors of hazard, and their measurement is useful for prognostication across the entire spectrum of HF disease severity. In patients with chronic HF, repeated determinations of NT-proBNP levels appear to convey additional prognostic value for relevant adverse outcomes, including death or HF hospitalization. Although "hard targets" for NT-proBNP values are not entirely defined, morbidity and mortality in chronic HF appear to increase markedly with an NT-proBNP concentration >1,000 ng/L. Confounding factors (such as renal function or obesity) should be kept in mind when prognostically evaluating patients using NT-proBNP measurements; however, the value of NT-proBNP is retained in these patients. Thus, serial assessment of NT-proBNP is valuable for prognostication in chronic HF in outpatients, and, as such, a measurement at each patient visit or the following of changes in clinical stability is recommended.
在慢性心力衰竭(HF)患者中,氨基末端前B型利钠肽(NT-proBNP)水平是最强的独立风险预测指标之一,其检测对于评估整个HF疾病严重程度谱的预后很有用。在慢性HF患者中,重复测定NT-proBNP水平似乎对包括死亡或HF住院在内的相关不良结局具有额外的预后价值。尽管NT-proBNP值的“严格目标”尚未完全明确,但当NT-proBNP浓度>1000 ng/L时,慢性HF的发病率和死亡率似乎会显著增加。在使用NT-proBNP检测对患者进行预后评估时,应考虑混杂因素(如肾功能或肥胖);然而,NT-proBNP在这些患者中的价值依然存在。因此,连续评估NT-proBNP对门诊慢性HF患者的预后评估很有价值,因此,建议在每次患者就诊时进行检测或跟踪临床稳定性的变化。